Hemostemix (CVE:HEM) Shares Up 29.4% – Here’s Why

Hemostemix Inc. (CVE:HEM)’s share price traded up 29.4% on Saturday . The stock traded as high as C$0.11 and last traded at C$0.11. 602,760 shares traded hands during trading, an increase of 511% from the average session volume of 98,700 shares. The stock had previously closed at C$0.09.

Hemostemix Stock Performance

The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The stock has a market capitalization of C$20.73 million, a PE ratio of -4.07 and a beta of 1.25. The firm has a 50 day moving average price of C$0.09 and a 200-day moving average price of C$0.10.

About Hemostemix

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.